



**Orientation Characteristics of kalifilcon A Daily Disposable Toric Contact Lenses  
Compared to Commercially Available Daily Disposable Toric Contact Lenses**

**CLINICAL INVESTIGATIONAL PLAN**

**STUDY: ROC2-23-007**

**IRB / B+L Reference Code #: AD23-01-00**

**PROJECT NAME:** 

Sponsor: Bausch & Lomb, Incorporated


This study is being conducted in accordance with 21CFR Parts 11, 50, 54, 56 and 812; 42 USC 282(j); ISO 14155:2020 Clinical investigation of medical devices for human subjects – Good Clinical Practice; International Council for Harmonization (ICH) Good Clinical Practice (GCP) - Declaration of Helsinki and applicable local regulations.

**Revision Chronology:**

**Version 1.0**

**August 9, 2023**

The information in the following document is confidential. The information contained herein will not be disclosed to others without written authorization from Bausch & Lomb, Incorporated.



**TABLE OF CONTENTS**

LIST OF ABBREVIATIONS/ACRONYMS ..... 5

INVESTIGATIONAL SITE AND STUDY PERSONNEL..... 6

SYNOPSIS..... 7

1.0 INTRODUCTION ..... 11

2.0 OBJECTIVE ..... 11

3.0 STUDY DESIGN..... 11

    3.1 Description of Study Design..... 11

    3.2 Selection of Study Population..... 11

        3.2.1 Eligibility ..... 12

            3.2.1.1 Inclusion Criteria ..... 12

            3.2.1.2 Exclusion Criteria ..... 13

        3.2.2 Point of Enrollment and Randomization..... 13

        3.2.3 Subject Completion..... 13

        3.2.4 Lost to Follow-up..... 14

    3.3 Investigators ..... 14

    3.4 Study Duration ..... 14

    3.5 Protocol Changes and Amendments ..... 14

4.0 STUDY MATERIALS ..... 14

    4.1 Description of the Test Lens: ..... 14

    4.2 Description of Comparator Lenses ..... 14

    4.3 Instructions for Use and Administration..... 15

        4.3.1 Storage Requirements ..... 15

        4.3.2 Subject Instructions..... 15

    4.4 Other Study Materials ..... 15

    4.5 Packaging and Labeling..... 16

    4.6 Accountability..... 16

    4.7 Masking..... 16

    4.8 Product Replacement ..... 17

    4.9 Risk Assessment ..... 17

        4.9.1 Risk Related to Subject..... 17

        4.9.2 Risk Related to Data Management ..... 17

    4.10 Relevance of Clinical Investigation ..... 18

5.0 STUDY METHODS.....	18
5.1 Measurements and Procedures.....	18
5.1.1 Study Visits.....	18
5.1.2 Unscheduled Visits.....	19
5.1.3 Missed Visits.....	19
5.1.4 Post-Study Follow-up Visit.....	19
5.2 Study Completion.....	19
5.2.1 Study Termination/Suspension.....	20
5.2.2 Study Termination Procedure.....	20
5.3 Concomitant Medications/Therapy.....	20
5.4 Protocol Deviations.....	20
6.0 ADVERSE EVENTS (AE).....	21
6.1 Adverse Event Definitions.....	21
6.1.1 Adverse Event (AE).....	21
6.1.2 Serious Adverse Event (SAE).....	21
6.1.3 Serious Adverse Ocular Event.....	22
6.1.4 Significant, Non-Serious Adverse Event.....	22
6.1.5 Non-significant, Non-serious Adverse Event.....	23
6.1.6 Adverse Device Effect (ADE).....	23
6.1.6.1 Anticipated Serious Adverse Device Effect (ASADE).....	23
6.1.6.2 Unanticipated Serious Adverse Device Effect (USADE).....	23
6.1.7 Device Deficiency.....	24
6.2 Adverse Event Treatment and Culturing.....	24
6.3 Adverse Event Identification and Evaluation.....	24
6.4 Adverse Event Collection and Reporting.....	25
6.5 Reporting Device Deficiencies.....	26
6.6 Emergency Contact Details for Reporting SAE and ADE.....	27
7.0 STATISTICAL METHODS.....	27
7.1 Study Endpoints.....	27
7.2 Hypotheses.....	27
7.3 Sample Size.....	27
7.4 Randomization.....	28
7.5 Study Populations.....	28

7.6 Statistical Analysis.....	28
7.6.1 Pass/Fail Criteria.....	28
7.6.2 Interim Analyses .....	28
7.6.3 Exploratory/Sensitivity Analysis .....	28
7.6.4 Deviations .....	28
8.0 DATA QUALITY ASSURANCE.....	28
8.1 Study Monitoring.....	29
8.1.1 Monitoring Subject Risk.....	29
8.1.2 Monitoring Informed Consent Process .....	29
8.1.3 Data Verification.....	30
8.1.3.1 Direct Entry with Verification .....	30
8.1.3.2 Double Entry of Data.....	31
8.1.3.3 The Data Management Summary (DMS).....	31
8.1.4 Annual Research Clinic Monitoring Plan.....	31
8.1.4.1 Monitoring Procedure .....	32
8.1.4.2 Site Performance Evaluation & Monitoring Report .....	32
8.2 Auditing Procedures.....	32
8.3 Source Documentation.....	32
8.4 Maintaining Subject Privacy.....	33
8.5 Locking the Database.....	33
8.6 Retention of Documents .....	34
8.7 Clinical Quality Assurance .....	34
8.8 Institutional Review Board .....	34
8.9 Statements of Compliance .....	34
8.10 Informed Consent Process .....	35
8.10.1 Vulnerable Population .....	35
8.11 Publication of Results .....	36
9.0 REFERENCES .....	36
APPENDIX A: METHODS OF CLINICAL EVALUATION.....	37
APPENDIX B: SUBJECT INSTRUCTIONS FOR USE.....	41

## LIST OF ABBREVIATIONS/ACRONYMS

Abbreviation/Acronym	Term
AE	Adverse Event
B+L	Bausch + Lomb
BSCVA	Best Spectacle-Corrected Visual Acuity
CFR	Code of Federal Regulations
CRT	Clinical Research Technician
CRF/e-CRF	Case Report Form / Electronic Case Report Form
EDC	Electronic Data Capture
EC	Ethics Committee
GCPs	Good Clinical Practices
GPRM	Global Pharmacovigilance and Risk Management
IB	Investigator's Brochure
IDE	Investigational Device Exemption
ICF	Informed Consent Form
IRB	Institutional Review Board
TMF	Trial Master File

NOTE: The first occurrence of some abbreviations is not spelled out in the document (e.g., units of measure).

**INVESTIGATIONAL SITE AND STUDY PERSONNEL**

The Investigators are Optometrists employed by Bausch & Lomb, Incorporated (Bausch + Lomb) and determined to be suitably qualified by training and experience to conduct this study. There are not any external organizations involved in the clinical investigation. Each Investigator may participate in all components of study execution. The study is paid for entirely by Bausch + Lomb. It will only be conducted at one site.

<b>Sponsor</b>	<b>Investigational Site</b>
Bausch & Lomb, Incorporated	Bausch & Lomb, Incorporated
1400 North Goodman Street	1400 North Goodman Street
Rochester, NY 14609	Rochester, NY 14609

<b>Principal Investigator</b>	<b>Sponsor/ Sponsor Representative</b>
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]

<b>Clinical Investigator</b>	<b>Emergency Contact</b>
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]

**SYNOPSIS**

<b>Study Title</b>	Orientation Characteristics of kalifilcon A Daily Disposable Toric Contact Lenses Compared to Commercially Available Daily Disposable Toric Contact Lenses
<b>Sponsor</b>	Bausch & Lomb, Incorporated, 1400 N. Goodman St. Rochester, NY 14609
<b>Number of Sites</b>	One Investigational Site, Bausch & Lomb Incorporated, Rochester, NY 14609
<b>Clinical Phase</b>	Device feasibility
<b>Trial Registration</b>	This study will be registered at clinicaltrials.gov.
<b>Test Articles</b>	<p><b>Test Lens:</b> kalifilcon A Daily Disposable Toric [REDACTED] (T01: kali A toric)</p> <p><b>Comparator Lenses:</b> Commercially available contact lenses                      C01: Total1 for Astigmatism (C01: Total1fA)                      C02: Precision1 for Astigmatism (C02: Precision1fA)                      C03: MyDay Toric (C03: MyDay Toric)</p>
<b>Objective</b>	The objective is to evaluate the contact lens fit characteristics [REDACTED] of kalifilcon A daily disposable toric compared to commercially available Total1 for Astigmatism, Precision1 for Astigmatism and MyDay Toric.
<b>Ethical Considerations</b>	Written approval of the protocol and informed consent will be provided to Bausch + Lomb by the IRB prior to initiation of the study. Investigators are not to deviate from the study protocol except when necessary for the protection of the subject’s health, safety, or welfare. Before any study-specific procedures are performed, the Investigator (or designee) will explain the purpose of the study, the associated procedures, and any anticipated effects or adverse reactions to the subject. The subject will be given sufficient time and opportunity to ask questions regarding any aspect of the study and to decide whether or not to participate in the study. Once the Investigator (or designee) is assured the subject understands the implications of study participation, the subject will be asked to give consent to participate in the study by signing and dating the Informed Consent Form (ICF).
<b>Study Design</b>	<p>Approximately 30 soft toric contact lens adapted subjects will be enrolled in this feasibility, bilateral, randomized, double-masked (subject and investigator), repeated measures insertion study. All subjects will be seen for a Screening/Dispensing Visit at which informed consent will be obtained and eligibility will be assessed. If subjects satisfy all eligibility criteria, subjects will be dispensed study lenses according to unique randomization tables that will be provided to each Investigator. If study eligibility is met, [REDACTED]</p> <p>[REDACTED]</p> <p>Subjects will be receiving each of the study lens types once, in a randomized order. [REDACTED]</p> <p>[REDACTED]</p>

<b>Study Duration/ Follow-up</b>	<p>There are a total of 4 study lens types. [REDACTED]</p> <p>Visit 1: Approximately 45 minutes</p> <p>The clinical investigation will take approximately 1 month to complete. Enrollment will take place throughout the duration of the study.</p>
<b>Treatment and Allocation Schedule</b>	<p>There are a total of 4 study lens types. [REDACTED]</p>
<b>Subjects Planned</b>	<p>Approximately 30 experienced soft contact lens wearing subjects (includes males and females). Healthy volunteers will be recruited and screened as per criteria outlined below. The subjects will all be experienced soft contact lens wearers.</p>
<b>Anticipated Study Population</b>	<p>Recruitment for this study will target experienced contact lens wearers that have refractive error requiring contact lens correction. Healthy male and female volunteers will be recruited and screened as per criteria outlined below.</p>
<b>Inclusion Criteria</b>	<p>To be eligible for entry into the study, the subject must:</p> <ol style="list-style-type: none"> <li>1. Be 18 years or older on the date the Informed Consent Form (ICF) is signed and have capacity to read, understand and provide written voluntary informed consent.</li> <li>2. Have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings.</li> <li>3. Have no active ocular disease or allergic conjunctivitis.</li> <li>4. Not be using any topical ocular medications.</li> <li>5. Be willing and able to follow instructions.</li> <li>6. Have signed a statement of informed consent</li> </ol>
<b>Exclusion Criteria</b>	<p>The subject is not eligible to participate in the study if the subject is:</p> <ol style="list-style-type: none"> <li>1. Participating in a conflicting study in the opinion of the Investigator.</li> <li>2. Considered by the Investigator to not be a suitable candidate for participation.</li> </ol>
<b>Disallowed Medications/ Interventions</b>	<p>Ocular, systemic or topical medications that, in the Investigator's opinion, could potentially affect ocular physiology or performance are prohibited.</p>
<b>Investigational Product, Dosage and Mode of Administration</b>	<p>Study lenses will be dispensed to subjects meeting all eligibility requirements including any dispensing requirements in this clinical protocol. Study lenses will be worn in office only. The investigator or designee will instruct all subjects to adhere to subject instructions.</p> <p>Subjects will be receiving each of the study lens types once, in a randomized order. The subject will wear each study contact lens pair for approximately 10 minutes.</p>





	[REDACTED]
	[REDACTED]
<b>Pass/Fail Criteria</b>	There are no pass/fail criteria for the results of the clinical investigation.
<b>Interim Analysis</b>	No interim analyses are planned.
<b>Monitoring Risk</b>	The risks involved with contact lens wear in this study will be minimized because the subjects will be examined frequently and at specified intervals. The risks are further minimized by the study eligibility criteria.
<b>Data Quality Assurance</b>	[REDACTED]

## 1.0 INTRODUCTION

The ability of a toric contact lens to orient correctly on-eye and to maintain that orientation [REDACTED] are important aspects of acceptable on-eye performance. Mechanical design features [REDACTED] are components of toric contact lens designs that are added to provide acceptable movement, orientation, and rotational stability needed to correct refractive astigmatism. Study ROC2-23-007 will evaluate [REDACTED] kalifilcon A daily disposable toric compared to Total1 for Astigmatism, Precision1 for Astigmatism, and MyDay Toric.

## 2.0 OBJECTIVE

The objective is to evaluate the contact lens fit characteristics [REDACTED] of kalifilcon A daily disposable toric compared to commercially available Total1 for Astigmatism, Precision1 for Astigmatism, and MyDay Toric.

## 3.0 STUDY DESIGN

### 3.1 Description of Study Design

Approximately 30 soft toric contact lens adapted subjects will be enrolled in this feasibility, bilateral, randomized, double masked (subject and investigator masked), repeated measures insertion study. All subjects will be seen for a Screening/Dispensing Visit at which informed consent will be obtained and eligibility will be assessed. If subjects satisfy all eligibility criteria and none of the exclusion criteria, [REDACTED] in random, successive order according to unique randomization schedules that will be provided to each Investigator.

[REDACTED]

The target is to have 30 subjects who are experienced contact lens wearers complete each study lens type. Further information regarding the target population can be found in the IB.

Visit 1: Approximately 45 minutes

The clinical investigation will take approximately 1 month to complete.

### 3.2 Selection of Study Population

Written informed consent, enrollment in the study, or dispensing of study products cannot begin until the Investigator has received Institutional Review Board (IRB)/Ethics Committee (EC) approval to conduct the study.

To reduce the foreseeable factors that could compromise the outcome of the clinical investigation, subjects are targeted who are experienced contact lens wearers. To be eligible to participate, subjects must have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings, no active ocular disease or allergic conjunctivitis, not using any topical ocular medications and be willing and able to follow instructions. There are no known or foreseeable factors that may compromise the outcome of this clinical investigation that are not already controlled for by the Inclusion and Exclusion criteria.

Healthy male and female volunteers will be recruited and screened as per criteria outlined below. The subjects will all be experienced soft contact lens wearers in both eyes.

Enrollment will take place throughout the duration of the study.

### **Intended Purpose/Use**

The kalifilcon A Daily Disposable [REDACTED] lenses are intended for the daily wear correction of refractive ametropia (myopia, hyperopia and astigmatism). Daily disposable lenses are to be prescribed for single use, daily disposable wear. The lenses are not intended to be cleaned or disinfected and should be discarded after a single use.

Additional information can be found in IB and in the comparator lens package insert, patient instruction booklet, and professional fitting guide<sup>1-8</sup>.

### **Investigational and Target Population**

The relationship between the investigative population and the target population is they are both contact lens wearers. Daily disposable toric lenses are for use by patients prescribed the correction of refractive ametropia (myopia, hyperopia and astigmatism), regardless of gender or ethnicity and who do not have contraindications for the device. This study will be conducted on adults of at least 18 years of age.

Recruitment for this study will target experienced soft contact lens wearers that have refractive error requiring contact lens correction. Subjects will be targeted that have a toric contact lens correction.

Additional information can be found in IB.

### **3.2.1 Eligibility**

#### **3.2.1.1 Inclusion Criteria**

To be eligible for entry into the study, the subject must:

1. Be 18 years or older on the date the Informed Consent Form (ICF) is signed and have capacity to read, understand and provide written voluntary informed consent.

2. Have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings.
3. Have no active ocular disease or allergic conjunctivitis.
4. Not be using any topical ocular medications.
5. Be willing and able to follow instructions.
6. Have signed a statement of informed consent.

### **3.2.1.2 Exclusion Criteria**

The subject is not eligible to participate in the study if the subject is:

1. Participating in a conflicting study in the opinion of the Investigator.
2. Considered by the Investigator to not be a suitable candidate for participation.

### **3.2.2 Point of Enrollment and Randomization**

The study is randomized. The study investigator and subject will be masked. An unmasked designee will be responsible for dispensing study products to the subjects according to the randomization schedule. The randomization schedule will be produced prior to study enrollment by Bausch + Lomb's unmasked statistician not otherwise involved in the study.

Randomization will be completed by the unmasked designee. The subjects will be assigned randomization numbers sequentially as they are enrolled. The unmasked designee is responsible for preparing the clinical trial materials according to the randomization schedule. The unmasked designee is also responsible for maintaining study lens inventory, randomization schedule and the Product Accountability Log in a masked fashion.

### **3.2.3 Subject Completion**

The subject will have completed the study when he/she has worn all of the study lens types. Subjects who require further follow-up due to an ongoing Adverse Event will be followed according to the Adverse Event Section 6.0.

The Investigator may discontinue a subject during the study for any reason if, in his or her opinion, it is in the best interest of the subject. Reasons for discontinuation include but are not limited to:

- adverse effects
- other ocular complications
- subject non-compliance
- subject request
- subject found to be ineligible during study participation\*

\*Any subject enrolled in the study, who later is found to have not met any of the eligibility criteria at entry, will be discontinued at the Sponsor's request.

Subject discontinuations will be documented clearly on the applicable case report form. Subjects that are discontinued from the study following randomization will not be replaced.

Exit visits should be completed for early terminated subjects.

The completion of the clinical investigation shall be deemed to coincide with the last visit of the last subject and when follow-up is complete.

### **3.2.4 Lost to Follow-up**

Subjects who do not return for scheduled follow-up visits, as defined by the visit window and cannot be contacted, are to be considered lost to follow-up. All attempts to contact the subject should be documented and kept with the subject's source documentation, and the applicable CRF/eCRFs will be completed.

### **3.3 Investigators**

The study will be conducted at one investigative site, the Bausch + Lomb Research Clinic in Rochester, NY by Investigators who are employed by Bausch + Lomb. The Investigators are qualified by training and experience to conduct this study. All the study procedures will be performed by Optometrists who are licensed to fit contact lenses.

The assessments required for the study are routinely performed by Optometrists and are standard of care for contact lens wearers. (See Appendix A: Methods of Clinical Evaluation for detailed information about study procedures).

### **3.4 Study Duration**

The clinical investigation will take approximately 1 month to complete.

### **3.5 Protocol Changes and Amendments**

Changes to the protocol will be approved by the Sponsor. An amendment to the protocol may also require submission and approval from the IRB before implementation. The Investigator is responsible for ensuring that staff involved have completed training on the changes before implementing with subjects.

## **4.0 STUDY MATERIALS**

Bausch + Lomb will provide all study materials. Subjects must use only study supplied contact lenses during the study visits. Use of other prescribed contact lenses and solution is not permitted during the study visits.

### **4.1 Description of the Test Lens:**

**Test Lens:** kalifilcon A Daily Disposable Toric [REDACTED] (T01: kali A toric)

### **4.2 Description of Comparator Lenses**

Comparator Lenses: Commercially available contact lenses

C01: Total1 for Astigmatism (C01: Total1fA)

C02: Precision1 for Astigmatism (C02: Precision1fA)

C03: MyDay Toric (C03: MyDay Toric)

More information on the commercially available study lenses can be found in the package inserts patient instruction booklets and professional fitting guide <sup>1-2</sup>.

#### **4.3 Instructions for Use and Administration**

Study lenses will be dispensed to subjects meeting all eligibility requirements including any dispensing requirements in this clinical protocol. Subjects will be dispensed an adequate supply of study lenses to complete the study. Lost or damaged study lenses may be replaced at the discretion of the Investigator. An unmasked designee will be responsible for all study lens accountability, including dispensation and collection of study supplies to subjects.

The investigator or designee will instruct all subjects to adhere to the Subject Instructions provided with their study contact lenses.

Subjects will be instructed not to use any other contact lenses or lens care products while wearing the study lenses.

The subjects will be masked to the study lenses. An unmasked designee at each site will be responsible for all study lens accountability, including dispensation and collection of study supplies to subjects.

Subjects will be receiving each of the study lens types once, in a randomized order. The subject will wear a pair of study contact lenses for approximately 10 minutes. See Appendix B for additional Instructions for Use.

##### **4.3.1 Storage Requirements**

All study materials provided by the Sponsor must be stored in a secure location accessible only to unmasked study personnel.

##### **4.3.2 Subject Instructions**

Subject Instructions for the use of study lenses are included in Appendix B, which include precautions and warnings related to contact lens wear. Subjects must comply with the instructions provided to them.

The Investigator or other designee must review, with the subject, the Subject Instructions and the precautions and warnings, as appropriate for the study.

Any subject who does not follow instructions to a degree that, in the Sponsor or Investigator's opinion, jeopardizes the subject's well-being or the validity of the study, should be discontinued.

#### **4.4 Other Study Materials**

Worn and unworn study lenses will be returned after the study is complete. No other study materials will be used in this study.

#### 4.5 Packaging and Labeling

**Test Lens:** kalifilcon A Daily Disposable Toric [REDACTED]

#### **Comparator Lenses: Commercially available contact lenses**

The comparator contact lenses will be packaged with commercial labels.

C01: Total1 for Astigmatism (C01: Total1fA)

C02: Precision1 for Astigmatism (C02: Precision1fA)

C03: MyDay Toric (C03: MyDay Toric)

#### 4.6 Accountability

The investigational site is responsible for keeping current and accurate records of the amount of study materials received and dispensed, and its disposition. The study lenses must be stored under the appropriate conditions in a secure area and are to be dispensed only to subjects enrolled in the study, in accordance with the conditions specified in this protocol.

All study materials will be accounted for on the Clinical Trial Materials Form and Lens/Solution Tracking Form. Subjects must return all remaining study materials to the Investigator at the final study visit, or their exit visit if discontinued prior to this visit.

#### 4.7 Masking

The investigators and subjects will be masked to the study lens types. Unmasked study personnel will be responsible for dispensing and collecting study lenses and accountability.

The randomization schedule will be created prior to the start of the study by an unmasked statistician not otherwise involved in the study.

In the event that unmasking of a subject's randomly assigned treatment is required, the Investigator (or designee) will reference the subject specific randomization schedule (or login to the EDC System) and unmask the subject.

Whether unmasking occurs inadvertently or intentionally, the Investigator must record the date, time, and reason for unmasking the study treatment in EDC System.



The contact lenses will be inserted into the subject's eye. The unmasked designee is not to show the study blister packs and foils to the Investigator or the subject. An effort will be made to conceal the study lenses from the subject and Investigator throughout the study.

#### **4.8 Product Replacement**

Not applicable, as subjects will not leave the office with study lenses for this insertion only study.

#### **4.9 Risk Assessment**

Information concerning potential risks associated with the investigational device (as well as possible interactions with concomitant medical treatments and risk-to-benefit ratio) can be found within the Investigator's Brochure. Risks are also summarized within the Informed Consent Form (ICF) document. The assessments required for the study are routinely performed and are standard of care for contact lens wearers. The subjects will be informed of any potential study specific risks in the ICF or if new risks become apparent during the study.

##### **4.9.1 Risk Related to Subject**

With contact lens wear there may be increased risk of corneal edema (swelling of the cornea) which may temporarily affect vision or comfort, neovascularization (small blood vessels growing into the cornea), giant papillary conjunctivitis (small bumps on the inside of the eyelids), iritis (internal inflammation in the eye), corneal infiltrates (corneal inflammation) and corneal erosion/abrasion or corneal infection, which if untreated may cause ocular problems.

The risks involved in this study will be minimized because the subjects will be examined frequently and at specified intervals. The risks are further minimized by the study eligibility criteria.

The subject may not personally benefit from being in this study other than getting the opportunity to wear different types of contact lenses. However, study results may allow a new or improved product to be marketed in the future giving benefit to other contact lens users.

No clinical benefit is expected from this feasibility study.

##### **4.9.2 Risk Related to Data Management**

[REDACTED]

[REDACTED]



#### **4.10 Relevance of Clinical Investigation**

Further information regarding the relevance of this study in the context of state-of-the-art clinical practice such as background information, summary of relevant literature, mechanism of action, intended clinical performance, and a summary of existing relevant clinical data of the investigational device can be found in the Investigator's Brochure.

### **5.0 STUDY METHODS**

The clinical procedures in this study are part of normal eye examination. There are not any deviations from normal clinical practice. The procedures conducted in the study are outlined below and described in Appendix A: Methods of Clinical Evaluation.

Following identification of a potential subject, the Investigator (or designee) will explain the purpose of the study, procedures, risks/benefits, and subject responsibilities to the potential subject. The subject's willingness and ability to meet the follow-up requirements of the study will be determined. If the subject chooses to participate in the investigation, written informed consent will be obtained. The subject and the person obtaining written consent will sign and date the IRB-approved ICF. The Investigator must keep the signed ICF document. The signed original document should be retained in the subject's records, and a copy should be provided to the subject. In addition, the applicable privacy regulation requirements must be met. Additional Informed Consent information is provided in Section 8.10.

### **5.1 Measurements and Procedures**

#### **5.1.1 Study Visits**

##### **Visit 1:**





### **5.1.2 Unscheduled Visits**

Additional visits may be scheduled, as necessary, to ensure the safety and well-being of subjects. All additional exams should be fully documented on Unscheduled Visit forms as appropriate.

### **5.1.3 Missed Visits**

If a subject misses a Study Visit, the visit is considered missed, and the subject must be exited from the study. The Investigator or designee must check the missed visit box on the first page of the applicable CRF/e-CRF for that visit.

See Section 3.2.4 Lost to Follow-Up for applicable instructions for subjects who do not return for the final visit.

### **5.1.4 Post-Study Follow-up Visit**

There is no planned follow-up period after the clinical investigation is complete. If a subject requires further follow-up upon discontinuation or completion of the study, the Investigator must schedule post-study follow-up visits, as necessary. The Investigator is required to follow the subject until the condition no longer warrants further follow-up for study purposes. A Post-Study Follow-up Visit e-CRF/CRF must be completed for each of these visits.

There will not be any routine eye care provided after the clinical investigation is complete. Subjects should follow-up with their eye care provider every 1-2 years for comprehensive eye care or sooner as recommended by their eye care provider.

## **5.2 Study Completion**

The subject has completed the study when the subject has completed all of the study lens types. Subjects who require further follow-up will be followed according to the Adverse Event or Post- Study Follow-Up Section. There is no planned follow-up period after the clinical investigation is complete.

The completion of the clinical investigation shall be deemed to coincide with the last visit of the last subject and when follow-up is complete.

### **5.2.1 Study Termination/Suspension**

If during the study it becomes evident that the study should be stopped prematurely or placed on hold, appropriate notification will be given to the requestor and IRB/ECs, as applicable. Should the Investigator and/or study requester wish to terminate the study, the following Research Clinic procedure will be followed. Any subjects with ongoing Adverse Events at the time of premature study termination or hold will be followed by the Investigator.

### **5.2.2 Study Termination Procedure**

The decision to terminate a study will be made by the Director, Vision Care Clinical Research and/or the Principal Investigator (PI). A final slit lamp examination should be performed, and adverse events handled accordingly. In the event that this study is suspended or terminated early, the Investigator (or designee) will reference the subject specific randomization schedule (or login to the EDC System) and unmask the subject.

All investigational materials (lenses, solutions, and / or devices) will be retrieved, all subjects will be exited and the Trial Master File will be reconciled. A clinical report will be written and include the reason for study termination.

### **5.3 Concomitant Medications/Therapy**

Ocular, systemic or topical medications that, in the Investigator's opinion, could potentially affect ocular physiology or lens/solution performance are prohibited.

### **5.4 Protocol Deviations**

The date of and reason for deviations will be documented in all cases. Significant or major protocol deviations impacting the safety of the subject or the integrity of the study must be reported by the Investigator to the IRB immediately. Reporting of all other protocol deviations must adhere to the requirements of the governing IRB/EC.

Any subject enrolled in the study who later is found to have not met the eligibility criteria at entry will be discontinued. Otherwise, unless the protocol deviations put the subject at risk or the subject's condition requires that they be discontinued from the study, subjects may continue to participate until the end of the study.

All investigators participating in this study agree to conduct the study in accordance with the relevant, current protocol and agree to only make changes in a protocol after being notified by the Sponsor, except when necessary to protect the safety, rights, or welfare of subjects. Under emergency circumstances investigators may proceed without prior approval of the IRB. These deviations will be documented and reported to the IRB as soon as possible. The sponsor will not grant protocol waivers for this study.

Corrective Action plans will be developed and completed as deemed necessary for Investigators who deviate from this protocol in a way that adversely affects the rights, safety or well-being of the subject(s) and/or the quality or integrity of data. The Corrective Action Plan will outline the deviation and the site's corrective and/or remedial actions.

Decisions regarding critical deviations that merit investigator disqualification and will be documented in the Trial Master File.

## **6.0 ADVERSE EVENTS (AE)**

Subjects who experience an adverse event during study participation will be discontinued from study participation but will be followed by the Investigator until resolution of the adverse event or until the Investigator determines that further improvement is not expected.

### **6.1 Adverse Event Definitions**

For the purposes of this study, reportable AEs include ocular AEs and non-ocular serious adverse events (SAEs). All AEs will be classified first for seriousness and significance and then as to whether or not they are device related or non-device related and if device related, then, if it is an adverse device effect (ADE), an anticipated serious adverse device effect (ASADEs) or an unanticipated serious adverse device effect (USADEs). AEs, ADEs, ASADEs, USADEs, SAEs, Significant Non-Serious AEs and Non-Significant Non-Serious AEs are defined as follows:

#### **6.1.1 Adverse Event (AE)**

Any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects or users, whether or not related to the investigational medical device. Adverse events should be categorized as device related or non-device related.

Throughout the course of this study all efforts will be made to remain alert to reportable AEs. If an AE occurs, the first concern will be the safety of the subject and appropriate medical intervention will be made.

All reportable AEs occurring after signing of informed consent and through the subject's end of participation in the study must be reported. All reportable AEs must be followed until the event resolves or stabilizes.

#### **6.1.2 Serious Adverse Event (SAE)**

An adverse event which:

- Led to death;
- Led to serious deterioration in the health of the subject, that resulted in:
  - A life-threatening illness or injury; or
  - A permanent impairment of a body structure or a body function (e.g., blindness); or
  - Inpatient or prolonged hospitalization; or
  - Medical or surgical intervention to prevent life-threatening illness or
  - Injury or permanent impairment to a body structure or a body function; or
  - Chronic disease
- Led to fetal distress, fetal death, or a congenital abnormality or birth defect.

### 6.1.3 Serious Adverse Ocular Event

Serious Adverse Ocular Event is a serious adverse event that results in, or has potential to cause, either permanent impairment of an ocular function or damage to an ocular structure and may necessitate medical or surgical intervention. Serious Adverse Events require expedited reporting. Serious adverse events include any hazardous, **sight-threatening conditions** occurring after exposure to a study lens, including but not limited to the following:

- A presumed infectious ulcer (defined as a progressive erosion of the corneal tissue). For the purposes of reporting, a corneal ulcer which has *any* of the following characteristics should be considered in this category:
  - Central or paracentral location;
  - Penetration of Bowman's membrane;
  - Infiltrate  $\geq 2$  mm diameter;
  - Associated with iritis;
  - Associated with any increase in intraocular pressure;
  - Culture positive for microorganisms;
  - Increasing size or severity at subsequent visits.

*Note: Signs of a presumed infectious ulcer may include irregular focal infiltrates; active lesions with raised edges; significant diffuse infiltration; anterior corneal to mid-stromal involvement; erosion with overlying staining; conjunctival and lid edema; anterior chamber reaction (iritis); severe bulbar and limbal redness. Symptoms associated with a presumed infectious ulcer (microbial keratitis) may include pain of rapid onset; severe redness; purulent or mucopurulent discharge; tearing; photophobia.*

- Any central or paracentral (within 6 mm of cornea) corneal event that results in permanent opacification (such as corneal scar or vascularization)
- Any serious adverse ophthalmic events including hypopyon and hyphema.
- Any neovascularization within the central 6 mm of the cornea.
- Permanent loss of 2 or more lines (10 letters) of Best Spectacle Corrected Visual Acuity (BSCVA).
- All cases of iritis.

### 6.1.4 Significant, Non-Serious Adverse Event

A Significant, Non-Serious Adverse Event is an Adverse Event that does not meet the serious criteria, is considered significant, and requires expedited reporting. These events include (but are not limited to):

- Peripheral non-progressive non-infectious corneal ulcer
- All symptomatic corneal infiltrative events
- All cases of corneal staining severity greater than or equal to Grade 3
- A temporary loss of 2 or more lines (10 or more letters) of BSCVA (for greater than or equal to 2 weeks)

- Increase in neovascularization of 1.5mm or greater.
- Any ocular event that necessitates temporary lens discontinuation of greater than or equal to 2 weeks.

#### **6.1.5 Non-significant, Non-serious Adverse Event**

A Non-Significant Non-Serious Adverse Event may include (but are not limited to) and does not require expedited reporting:

- Asymptomatic, peripheral, corneal infiltrative events.
- Bacterial Conjunctivitis
- Viral Conjunctivitis
- Allergic Conjunctivitis
- Corneal Edema
- Contact Lens Related Papillary Conjunctivitis

#### **6.1.6 Adverse Device Effect (ADE)**

An ADE is an Adverse Event that is assessed to be related to the use of an investigational medical device. This definition includes Adverse Events resulting from insufficient or inadequate instructions for use; deployment, implantation, installation, or operation; or any malfunction of the investigational medical device. This definition also includes any event resulting from use error or from intentional misuse of the investigational medical device.

##### **6.1.6.1 Anticipated Serious Adverse Device Effect (ASADE)**

An ASADE is an ADE that first meets the serious criteria (see definition above for Serious Adverse Event) or significant, non-serious criteria (see above definition for significant, non-serious AE) and which, by its nature, incidence, severity or outcome, has been previously identified in the investigational plan or application (including a supplementary plan or application) and/or in the risk analysis report. ASADEs include:

- Corneal Ulcer (infectious or non-infectious)
- Keratitis
- Sensitivity to light (photophobia)
- Excessive eye secretions including mucopurulent discharge
- Blurred vision, rainbows or halos around objects
- Poor visual acuity (reduced sharpness of vision)
- Moderate to severe eye pain not relieved by removing the lens

##### **6.1.6.2 Unanticipated Serious Adverse Device Effect (USADE)**

An USADE is an ADE that first meets the serious criteria (see definition above for Serious Adverse Event) or significant, non-serious criteria (see above definition for significant, non-serious AE) and has an effect on health or safety or any life-threatening problem or death caused by, or associated with, a device if that effect, problem or death was not previously identified in nature, severity or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects.

### **6.1.7 Device Deficiency**

Inadequacy of an investigational medical device with respect to its identity, quality, durability, reliability, safety, or performance. This includes malfunctions, use errors, inadequate labelling, insufficient or inadequate instructions for use. A Device Deficiency can occur with or without the occurrence of an Adverse Event.

### **6.2 Adverse Event Treatment and Culturing**

With any Adverse Event, treat the subject as appropriate to prevent further complications and to potentially resolve the event consistent with the standard of care.

A culture should be obtained in cases of corneal ulcer or suspected ocular infection, unless medically contraindicated. Cultures should be taken from the cul-de-sac, lower eyelid margin, and the corneal lesion (if applicable). When a culture is obtained, the contact lenses and contact lens cases which were being utilized by the subject at the time of the AE should be collected from the subject (if available at the time of the culture) for culturing and processing by the clinical laboratory designated by the Research Clinic. Microbial data generated from returned subject supplies (e.g., lenses, lens cases and/or lens case solutions) are for information only. Because microbes may be introduced into subject supplies during use, recovery of microbes from returned subject supplies cannot be presumed to indicate etiology or direction of organism transmission. The ocular cultures, along with the associated contact lenses and contact lens cases, will be sent to the clinical laboratory designated by the Research Clinic for analysis. The clinical laboratory will report the culture results to both the Investigator and to the Research Clinic, the Investigator will record the results in the applicable form.

### **6.3 Adverse Event Identification and Evaluation**

Throughout the course of a study all efforts will be made to remain alert to Adverse Events (AEs). If an AE occurs, the first concern will be the safety of the subject and appropriate medical intervention will be made. The associated product should be retained for further analysis, if needed.

All AEs occurring after signing the informed consent and through the end of the subject's participation in the study must be recorded and reported, if applicable. All AEs must be followed until the event resolves or stabilizes.

Identify potential adverse events during a clinical study by using the following sources:

- Direct observation by the Investigator
- Asking the study participant using a non-specific question (i.e. Have you had any problems since the last visit?)
- Unsolicited volunteering of information by the study participant (i.e. Doctor, I have had numerous headaches since I started using this lens)
- Laboratory or test results that meet protocol requirements for classification as an adverse event (i.e. IOP over 30mmHg)



- When evaluating AEs, the Investigator should classify the AE based on the following three criteria: **Seriousness and/or significance** (based on the criteria provided in Section 6.1)
1. **Severity:**
    - **Mild:** Subject awareness of a sign or symptom that is easily tolerated, requires no treatment, and does not interfere with subject's daily activities.
    - **Moderate:** Subject awareness of a sign or symptom which may be a low level of concern to the subject and may interfere with daily activities but can be relieved by simple therapeutic care.
    - **Severe:** A sign or symptom that interrupts the subject's daily activity and requires systemic therapy or other treatment.
  2. **Relationship of the event to the study device** using the following guidelines:
    - **Related:** There is at least a reasonable possibility that the AE is related to the study device (contact lens) and/or solution or rewetting drops. Reasonable possibility means that there is evidence to suggest a causal relationship or association between the study device and/or solution or rewetting drops and the AE. Also referred to as an ADE.
    - **Not Related:** There is little or no reasonable possibility that the AE is related to the study device (contact lens) and/or solution or rewetting drops. This assessment implies that the AE has no evidence to suggest either a causal relationship or association to the study device and/or solution or rewetting drops and a more likely or certain alternative etiology exists.
  3. **Expectedness of the event**
    - **Unexpected Adverse Event (UAE):** Unexpected Adverse Events must be reported to the IRB within 10 calendar days of discovery.
    - **Expected Adverse Event:** An adverse event of which, the nature or severity of which is consistent with the current product labeling, investigator brochure, data sheet, etc.



[Redacted]

[Redacted]

**6.5 Reporting Device Deficiencies**

[REDACTED]

[REDACTED]

## 7.0 STATISTICAL METHODS

### 7.1 Study Endpoints

The primary endpoint is Primary gaze orientation 5 minutes after lens insertion.

### 7.2 Hypotheses

[REDACTED]

### 7.3 Sample Size

[REDACTED]



#### **7.4 Randomization**

To minimize or avoid bias, subjects will be assigned randomization numbers as they are enrolled according to unique randomization schedules created for the study. The randomization schedule will be produced prior to study enrollment. Subjects will be receiving each of the study lens types once, in a randomized order.

The randomization schedule is verified up to 5 times during the course of the study: The CRT visually verifies the study material against the randomization schedule during CTM preparation (if applicable) and before dispensing any study materials. The randomization schedule is also verified in EDC after dispensing the CTM. Once the study is complete, randomization is verified again during CTM reconciliation. Upon completion of the study, the EDC programmer also verifies randomization.

#### **7.5 Study Populations**

Subjects will be included in all summaries under the treatment that they actually received. Analyses of safety data will include all dispensed subjects. All other summaries will include all eligible, completed subjects.

#### **7.6 Statistical Analysis**



##### **7.6.1 Pass/Fail Criteria**

There are no pass/fail criteria for the results of the clinical investigation.

##### **7.6.2 Interim Analyses**

No interim analyses are planned.

##### **7.6.3 Exploratory/Sensitivity Analysis**

There are no planned exploratory or sensitivity analyses for this study.

##### **7.6.4 Deviations**

Any deviations from the original statistical analysis plan will be summarized in the Clinical Study Report.

#### **8.0 DATA QUALITY ASSURANCE**

Steps will be taken to ensure the accuracy and reliability of data, including the selection of qualified investigators and review of protocol procedures. Prior to the start of the study,

member(s) of the Research Clinic and Investigators will review the protocol, e-CRFs, regulatory obligations, and other material or equipment relevant to the conduct of the study. The Principal Investigator, in turn, must ensure that all Sub-Investigators and clinical personnel are familiar with the protocol and all study-specific procedures and have appropriate knowledge of the study article. The CRT's are trained on completing case report forms.

The data for this study will be captured on electronic case report forms using an EDC System (Inform). Inform is a fully validated EDC system and is compliant with 21 CFR Part 11. Once the EDC system is installed, test scripts are completed to test the functionality of Inform and ensure the system is complaint. Documentation of compliance with 21 CFR Part 11 is on file with B+L Quality. The clinical data will be recorded on dedicated eCRF's specifically designed to match the study procedures for each visit.

Once completed, the eCRF's will be reviewed for accuracy and completeness and signed by the Investigator. The database will them be locked. Each user has his/her own username and password. Only registered users assigned to the study can login to the clinical study.

[REDACTED]

During the study, if it is determined that an Investigator is not compliant with the protocol and/or applicable regulatory requirements, action will be taken to secure compliance. In addition, the Investigator's participation in the study may be terminated if appropriate, or if the Investigator remains non-compliant.

[REDACTED]

## **8.1 Study Monitoring**

The monitoring plan for this study includes Informed Consent and Data Verification.

### **8.1.1 Monitoring Subject Risk**

The risks involved with contact lens wear in this study will be minimized because the subjects will be examined frequently and at specified intervals. The risks are further minimized by the study eligibility criteria. The subject population will be restricted to persons who are 18 years of age or older and have full legal capacity to volunteer; no restrictions are made as to gender.

### **8.1.2 Monitoring Informed Consent Process**

[REDACTED]

[REDACTED]

### 8.1.3 Data Verification

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

#### 8.1.3.1 Direct Entry with Verification

[REDACTED]

[REDACTED]

**8.1.3.2 Double Entry of Data**

[REDACTED]

[REDACTED]

**8.1.3.3 The Data Management Summary (DMS)**

A Data Management Summary is created after all data has been verified.

**8.1.4 Annual Research Clinic Monitoring Plan**

[REDACTED]

[REDACTED]

#### **8.1.4.1 Monitoring Procedure**

[REDACTED]

#### **8.1.4.2 Site Performance Evaluation & Monitoring Report**

[REDACTED]

### **8.2 Auditing Procedures**

Audits of clinical research activities in accordance with Bausch + Lomb's internal Standard Operating Procedures to evaluate compliance with the principles of GCP may take place. A regulatory authority may also wish to conduct an inspection (during the study or after its completion).

### **8.3 Source Documentation**

Source documentation consists of original subject documents, as well as data and records with information relevant to the subject and his/her participation in the study. The data collected in the CRF/e-CRFs at all the visits will be available to the Investigator after the conclusion of the trial.

Examples of source documents include hospital records, clinical and office charts, laboratory notes, memoranda, signed ICF, evaluation checklists, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate copies, and information initially recorded in an electronic format.



Subject completed forms are also considered to be source data, if applicable to the study. The Investigator or designee should review subject completed forms for completeness and accuracy.

#### **8.4 Maintaining Subject Privacy**

Subject data recorded on eCRFs during the study will be documented in a coded fashion. The subject will only be identified by the subject number and by their initials if also required. Confidentiality of subject records must be maintained to ensure adherence to applicable local privacy regulations.

Subjects' participation in this study and their study records (including photographs and video/audiotapes) will be held in a way that will protect their privacy, except when ordered by law. It may be necessary for other people to review their records for study reasons. These people may include:

- The Investigator
- The United States Food and Drug Administration (FDA)
- Other state or federal regulatory agencies
- The Institutional Review Board (IRB)
- Contracted monitors or auditors
- Bausch + Lomb personnel associated with the study analysis and reporting

If this occurs, their identity will be protected as legally required. If results of the study are published, subjects will not be identified by name.

The Institutional Review Board (IRB) and accrediting agencies may inspect and copy subjects' records, which may have the subjects' name on them. Therefore, total confidentiality cannot be guaranteed. If the study results are presented at meetings or printed in publications, subject names will not be used.

Data pertaining to subjects is only available to Bausch + Lomb personnel. Physical data remains locked and electronic data is password protected. When subjects receive an electronic recruitment invitation, all other potential subjects are blind carbon copied on the invitation to ensure patient privacy.

Clinical trial data is input into a secure, electronic data capture system in which only relevant study personnel have access. Subject data recorded on CRF/e-CRFs during the study will be documented in a coded fashion. The subject will only be identified by the subject number. Confidentiality of subject records must be maintained to ensure subject privacy.

#### **8.5 Locking the Database**

After the study is complete, the data is approved by the Principal Investigator via electronic signature. The database is then locked. Any change to the data after database lock will

require approval from the EDC Programmer and is documented via electronic audit trail.

### **8.6 Retention of Documents**

Bausch + Lomb must retain essential documents indefinitely after the completion of the study. The Research Clinic keeps physical study related documents physically on-site for a minimum of 3 years. After 3 years, the documents may be securely stored in an off-site location. Additionally, data is securely stored electronically.

Essential documents include but are not limited to the following:

- IRB approvals for the study protocol, all amendments, ICF(s), and advertisements
- IRB correspondence and reports (e.g., AE reports, protocol deviations, and safety updates)
- regulatory documents
- subject's signed ICF
- accountability records for the test article(s)
- any other documents relevant to the conduct of the study

### **8.7 Clinical Quality Assurance**

Prior to being evaluated clinically, investigational devices such as contact lenses or solutions are analyzed and approved for release by the project manager and design quality at Bausch and Lomb, Rochester, NY. Documentation of pre-clinical testing can be found on the study's clinical scorecard for the relevant products.

For the commercially available competitor products, information can be found in the respective package inserts, patient instruction booklets, professional fitting guides and in the IB<sup>1-8</sup>.

### **8.8 Institutional Review Board**

The Investigator should ensure their participation in the study, in addition to the protocol, subject recruitment materials and the ICF to be used in this study are approved by the reviewing IRB prior to entering any subjects in the study. In addition, the Investigator must ensure that the reviewing IRB has provided approval for any protocol amendments prior to implementation. If the amendment necessitates a revision to the ICF, the Investigator should ensure the revised form is also submitted to and approved by the IRB and implemented as directed.

### **8.9 Statements of Compliance**

This study is being conducted in accordance with 21CFR Parts 11, 50, 54, 56 and 812; 42 USC 282(j); ISO 14155:2020 Clinical investigation of medical devices for human subjects – Good Clinical Practice; International Council for Harmonization (ICH) Good Clinical Practice (GCP) - Declaration of Helsinki and applicable local regulations.

The devices for this study conform to applicable general safety and performance requirements apart from aspects covered by the clinical investigation and that, with regard

to those aspects, every precaution has been taken to protect the health and safety of the subjects.

This clinical investigation will demonstrate compliance with this document.

The clinical investigation shall not begin until the required approval from the IRB has been obtained. Any additional requirements imposed by the IRB shall be followed.

No insurance will be provided to the subjects.

Bausch + Lomb is financing this clinical investigation. The investigators are paid employees of Bausch + Lomb.

### **8.10 Informed Consent Process**

All subjects will be given a copy of the Informed Consent Form (ICF) to read prior to enrollment. Subjects will have an opportunity to ask questions prior to enrollment and throughout the study. The ICF also contains information on payment for participating in the study. All subjects will need to sign the ICF prior to participation in the study. The person obtaining informed consent will also sign and date the form. The subject's signed informed consent must be obtained before conducting any study related procedures. The original will be retained by the investigative site. A copy of the signed ICF will be given to the subject. If modifications are made to the ICF, the new version must be approved by the IRB. The new version of revised ICF(s) must be reviewed and signed by all active (if required by the IRB) and new subjects at the first opportunity after approval by the IRB.

For this study, subjects will have the capacity to provide written voluntary informed consent. Emergency treatment is not applicable. No minors or those who cannot speak English or read or write will be recruited for this study.

#### **8.10.1 Vulnerable Population**

[REDACTED]

[REDACTED]

All subjects will be given a copy of the Informed Consent Form (ICF) to read and will also have an opportunity to ask questions to the Investigator or designee prior to enrollment. All subjects will need to sign the Informed Consent Form prior to participation in the study.

[REDACTED]

After the study is complete, there is no planned/routine medical follow-up care.

## 8.11 Publication of Results

All study data generated as a result of this study will be regarded as confidential, until appropriate analysis and review by Bausch + Lomb or its designee and the Investigator(s) are completed. The results of the study may be published or presented by Bausch + Lomb.

## 9.0 REFERENCES

1. Dailies Total1 for Astigmatism Package Insert.  
[http://embed.widencdn.net/pdf/plus/alcon/xe3t4jzpll/W900038292\\_I\\_DELFCON\\_US.pdf?u=4rqn%209d](http://embed.widencdn.net/pdf/plus/alcon/xe3t4jzpll/W900038292_I_DELFCON_US.pdf?u=4rqn%209d)
2. Dailies Total1 for Astigmatism Patient Instruction Booklet.  
[http://embed.widencdn.net/pdf/plus/alcon/kaaikddkvz/W900060572\\_PB\\_DELFA\\_US.pdf?u=4rqn9d](http://embed.widencdn.net/pdf/plus/alcon/kaaikddkvz/W900060572_PB_DELFA_US.pdf?u=4rqn9d)
3. Dailies Total1 for Astigmatism Professional Fitting Guide.  
[https://p.widencdn.net/7utjdt/W900236422\\_PFIG\\_DELFCON\\_A\\_US](https://p.widencdn.net/7utjdt/W900236422_PFIG_DELFCON_A_US)
4. Precision1 for Astigmatism Package Insert. <https://alcon.widen.net/s/hqk29vrghm>
5. Precision1 for Astigmatism Patient Instruction Booklet.  
<https://alcon.widen.net/s/rfkcrmb8p>
6. Precision1 for Astigmatism Professional Fitting Guide.  
<https://alcon.widen.net/s/fphscnjggw>
7. CooperVision Stenfilcon A Soft (Hydrophilic) Contact Lenses Single Use Daily Disposable Wear Practitioner Fitting Guide.  
[https://coopervision.com/sites/coopervision.com/files/pfg01013-\\_myday-stenfilcon-a-asphere-toric-multifocal-and-multifocal-toric-lensespfg-rev-d.pdf](https://coopervision.com/sites/coopervision.com/files/pfg01013-_myday-stenfilcon-a-asphere-toric-multifocal-and-multifocal-toric-lensespfg-rev-d.pdf)
8. CooperVision MyDay Soft (Hydrophilic) Daily Disposable Contact Lenses package insert. <https://coopervision.com/sites/coopervision.com/files/pi01100-myday-stenfilcon-a-asphere-toric-multifocal-and-multifocal-toric-lenses-pi-rev-d.pdf>

**APPENDIX A: METHODS OF CLINICAL EVALUATION**

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]


[REDACTED]



## 2.0 PERFORMANCE RATING

Performance rating scales are used for collecting subjective data for clinical studies.







**APPENDIX B: SUBJECT INSTRUCTIONS FOR USE**

**CAUTION:** Investigational device. Limited by Federal (U.S.A.) Law to investigational use only.

**INTRODUCTION**

As a participant in this study, you will wear [REDACTED]  
[REDACTED] You will wear the study lens types in a randomized order.

Do not discuss or describe the study or the study materials with anyone except the person who gave you the study materials at the Screening/Dispensing Visit. You should not show the study blister packs and foils to the Investigator unless instructed to do so.

**STUDY PRODUCT INFORMATION**

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Do not use any other contact lenses, eye drops or lens care products than those listed above while you are wearing the study lenses.

All study materials, used and unused, must be returned.

**If you have questions or problems, call:**

[REDACTED]

If you require a medical referral for any eye problems experienced during the study, please refer to your informed consent form.

**GENERAL INFORMATION**

Please keep all appointments and follow the instructions thoroughly. Remember to wear your glasses to your appointments.

These subject instructions apply to all study lens types. For all study lenses, it is essential to your safety that you read and understand the information and instructions in these subject instructions, and have your questions answered before and after you receive contact lenses.

Wearing contact lenses is different from wearing eyeglasses. Because they are worn directly on your eyes, contact lenses affect the way in which your eyes function. These effects tend to increase with the length of time that the lenses remain on your eyes between removals. Although the great majority of people successfully wear contact lenses without problems, before you decide whether to begin or to continue wearing contact lenses, you should discuss with the study investigator the effects of contact lenses on your eyes and the risks associated with wearing contact lenses. You also should read the sections in these subject instructions entitled "Warnings", "Adverse Reactions", "Precautions", and "Wearing Restrictions and Indications". Ask the investigator to explain anything that you do not understand, including any additional restrictions which may be given to you.

You also need to remember that soft contact lenses, including those covered by these subject instructions, are made of a type of plastic that absorbs liquids, vapors, and small particles, and, for some people, may collect deposits from your natural eye fluids. Therefore, you should strictly follow the instructions contained in these subject instructions entitled "Personal Cleanliness and Lens Handling", and any other instructions given to you by your eye care professional. Any failure to follow these instructions and the wearing restrictions will increase the chances of contamination, damage to the lenses, or a build-up of deposits on the lenses, which can lead to serious, sight-threatening eye infections and injuries.

If problems or symptoms should occur, immediately remove your contact lenses and follow the steps described in the sections in these subject instructions entitled "Warnings" and "Adverse Reactions". Prompt attention to problems is essential and may require immediate professional care.

Remember, when wearing soft contact lenses your eyes should look and feel good, and your vision should be clear.

### **WEARING RESTRICTIONS AND INDICATIONS**

The study lenses are indicated for the correction of refractive ametropia (myopia, hyperopia and astigmatism) in persons with non-diseased eyes.

### **WARNINGS**

You should be aware of and fully discuss with the study investigator the following warnings pertaining to contact lens wear:

- Problems with contact lenses could result in **serious injury** to your eye. It is essential that you follow your eye care professional's direction and all labeling instructions for proper use of lenses. Eye problems, including corneal ulcers, can develop rapidly and lead to **loss of vision**.

- Strict compliance with your wearing restrictions, wearing schedule, and follow-up visit schedule must be followed.
- Clinical studies have shown that the risk of serious adverse reactions is increased when daily wear lenses are worn overnight. Study lenses should not be worn overnight.
- Studies have shown that contact lens wearers who are smokers have a higher incidence of adverse reactions than nonsmokers.
- If you experience eye discomfort, excessive tearing, vision changes, or redness of the eye, you should **immediately remove lenses** and promptly contact your eye care professional.

### **PRECAUTIONS**

You should be aware of and fully discuss with your eye care professional the following safety precautions:

#### **Lens Handling Precautions**

- Always wash and rinse hands before handling lenses. Do not get cosmetics, lotions, soaps, creams, deodorants, or sprays in the eyes or on the lenses. It is best to put on lenses before putting on makeup. Water-base cosmetics are less likely to damage lenses than oil-base products.
- Do not touch contact lenses with your fingers or hands if your hands are not free of foreign materials, as microscopic scratches of the lenses may occur, causing distorted vision and/or injury to your eye.
- Do not use saliva or anything other than the recommended solutions for lubricating or wetting your lenses.
- Be certain that the fingers or hands are free of foreign materials before touching your lenses, as microscopic scratches of the lenses may occur, causing distorted vision and/or injury to the eye.
- Always handle your lenses carefully and gently and avoid dropping them.
- Always hand the same lens (right or left) to avoid mix-ups.
- Do not touch the lens with your fingernails.
- Carefully follow the handling, insertion, removal, storing and wearing instructions in these subject instructions and those prescribed by the study investigator.
- Never use tweezers or other tools to remove your lenses from the lens container unless specifically indicated for that use. Pour the lens into the hand.

#### **Lens Wearing Precautions**

- Never wear your lenses beyond the period recommended by your eye care professional.
- If the lens sticks (stops moving) on the eye, follow the recommended directions on Care for a Sticking (Nonmoving) Lens. The lens should move freely on the eye for the continued health of the eye. If nonmovement of the lens continues, you should **immediately** consult

your eye care professional.

- Avoid, if possible, all harmful or irritating vapors and fumes when wearing lenses.
- If aerosol products are used while wearing lenses, exercise caution and keep eyes closed until the spray has settled.

**Topics to Discuss with the Eye Care Professional:**

- You should not wear contact lenses during water related activities. Exposure to water while wearing contact lenses in activities such as swimming, water skiing and hot tubs may increase the risk of ocular infection including but not limited to *Acanthamoeba* keratitis.
- Always contact your eye care professional before using any medicine in the eyes.

**Who should know that you are wearing contact lenses?**

- You may decide to inform your health care professional about being a contact lens wearer.
- Always inform your employer of being a contact lens wearer. Some jobs may require the use of eye protection equipment or may require that you not wear lenses.
- Ask the study investigator whether there are any other wearing restrictions that apply to you. Write those restrictions in the spaces provided below and follow them carefully:

---

---

---

---

**ADVERSE REACTIONS (PROBLEMS AND WHAT TO DO)**

You should be aware that the following problems may occur:

- Eyes stinging, burning, itching (irritation), or other eye pain
- Comfort is less than when lens was first placed on eye
- Abnormal feeling of something in the eye (foreign body, scratched area)
- Excessive watering (tearing) of the eyes
- Unusual eye secretions
- Redness of the eyes
- Reduced sharpness of vision (poor visual acuity)
- Blurred vision, rainbows, or halos around objects
- Sensitivity to light (photophobia)
- Dry eyes

If you notice any of the above, you should:

**Immediately remove your lenses.**

- If the discomfort or problem stops, then look closely at the lens. If the lens is in any way damaged, **do not** put the lens back on your eye. You should remove the lens and place it in the provided contact lens case dry. Then insert a new lens on the eye. If the problem

continues, you should **immediately remove the lenses and consult your eye care professional.**

When any of the above problems occur, a serious condition such as infection, corneal ulcer, neovascularization, or iritis may be present. You should **keep the lens off your eye and seek immediate** professional identification of the problem and prompt treatment to avoid serious eye damage.

## **PERSONAL CLEANLINESS, LENS CARE AND LENS HANDLING:**

### **1. Preparing the Lens for Wearing:**

It is essential that you learn and use good hygienic methods in the care and handling of your new lenses. Cleanliness is the first and most important aspect of proper contact lens care. Your hands should be clean and free of any foreign substances when you handle your lenses. The procedures are:

- Always wash your hands thoroughly with a mild soap, rinse completely, and dry with a lint-free towel before touching your lenses.
- Avoid the use of soaps containing cold cream, lotion, or oily cosmetics before handling your lenses, since these substances may come into contact with the lenses and interfere with successful wearing.
- Handle your lenses with your fingertips and be careful to avoid contact with fingernails. It is helpful to keep your fingernails short and smooth.
- Start off correctly by getting into the habit of always using proper hygienic procedures so that they become automatic.

### **2. Handling the Lenses:**

- Develop the habit of always working with the same lens first to avoid mix-ups.
- Position the lens on your index finger and examine it to be sure that it is moist, clean, clear, and free of any nicks or tears.
- Should you accidentally place an inside-out lens on your eye, one of the following signs should signal you to remove and replace it correctly.
  - a) Less than usual comfort,
  - b) The lens may fold on the eye,
  - c) Excessive lens movement on blink,
  - d) Blurred vision.
- If the lens folds and sticks together: Place the lens in the palm of your hand and wet thoroughly with the recommended rinsing or storing solution. Then GENTLY rub the lens between your index finger and palm in a gentle back and forth motion.
- If the lens flattens or drapes across your finger, the lens or your finger may be too wet. To correct this, dry your finger by transferring the lens several times from one index finger to the other, drying the opposite finger each time.

### 3. Placing the Lens on the Eye

There are other methods of lens placement. If the following methods are difficult for you, your Study Doctor will provide you with an alternate method.

**NOTE: If after placement of the lens, your vision is blurred, check for the following:**  
The lens is not centered on the eye (see “Centering the Lens,” next in these instructions).


If the lens is centered, remove the lens (see “Removing the Lens” section) and check for the following:

- cosmetics or oils on the lens (replace the lens)
- the lens is on the wrong eye
- the lens is inside-out (it would also not be as comfortable as normal)

If you find that your vision is still blurred after checking the above possibilities, remove both lenses and consult your eye care professional.

#### A. The One-Hand Placement Technique

- Place the lens on your index finger. Head up, looking straight ahead, pull down your lower eyelid with the middle finger of your placement hand. Look up steadily at a point above you. Then place the lens on the lower white part of your eye. Remove your index finger and slowly release the lower lid. Look down to position the lens properly. Close your eyes for a moment; the lens will center itself on your eye.



#### B. The Two-Hand Placement Technique

- With the lens on your index finger, use the middle finger of the other hand to pull the upper lid against the brow. Use the middle finger of your placement hand to pull down the lower lid and then place the lens centrally on your eye. While holding this position, look downward to position the lens properly. Slowly release your eyelids.
- If the lens feels uncomfortable, then look in the mirror and gently place a finger on the edge of the contact lens and slowly slide the lens away from your nose while looking in the opposite direction. Then by blinking, the lens will re-center itself. If the lens still feels uncomfortable, follow the steps described in the section of these instructions entitled “Adverse Reactions.”



#### **4. Centering the Lens**

Very rarely, a lens that is on the cornea will be displaced onto the white part of the eye during lens wear. This can also occur during placement and removal of the lenses if the correct techniques are not performed properly. To center a lens, follow one of the procedures below.

- Hold the upper and lower eyelids open with your fingers. Then while looking in a mirror, gently place a finger on the contact lens and gently slide the lens towards the center of the eye.

OR

- Hold the upper and lower eyelids open with your fingers. Then, while looking in a mirror, move your eye towards the lens to place it on the center of the eye.

#### **5. Removing the Lens**

- Always remove the same lens first.
- Wash, rinse, and dry your hands thoroughly.
- Always be sure that the lens is in the correct position on your eye before you try to remove it (a simple check of your vision, closing one eye at a time, will tell you if the lens is in the correct position). Look up and slowly pull down your lower eyelid with the middle finger of your removal hand and place your index finger on the lower edge of lens. Squeeze the lens lightly between the thumb and the index finger and remove it. Avoid sticking the edges of the lens together.
- Remove the other lens by following the same procedure.
- Follow the required lens care procedures described by your eye care professional.
- NOTE: If this method of removing your lens is difficult for you, your eye care professional will provide you with an alternate method.

#### **6. Care for a Sticking (Nonmoving) Lens**

- It is important to the health of your eyes that your contact lenses move freely. If a lens sticks (stops moving), put a few drops of the Bausch + Lomb Sensitive Eyes® Drops provided by your study doctor into your eye. In this case, do not use plain water or anything other than the recommended solutions. Do not attempt to remove a lens that is sticking, which could damage your eye. If the lens does not begin to move when

you blink after several applications of the solution or, contact your study doctor immediately. Do not attempt to remove the lens except on the advice of your study doctor.

**7. Return of Your Study Lenses**

Do not discard worn lenses. At each visit, you must return all used and unused study materials that were dispensed to you during the designated wear periods.

**8. Emergency:**

If chemicals of any kind (household products, gardening solutions, laboratory chemicals, etc.) are splashed into your eyes, you should: **FLUSH EYES IMMEDIATELY WITH TAP WATER AND THEN REMOVE LENSES PROMPTLY. CONTACT YOUR EYE CARE PROFESSIONAL OR VISIT A HOSPITAL EMERGENCY ROOM WITHOUT DELAY.**



